01 Apr Ocugen
Abhi Gupta, Executive Vice President of Commercial & Business Development
April 28 | 4:30pm | Salone dei Cavalieri, Section 1
Malvern, PA
(NASDAQ: OCGN)
Ocugen is a pioneering biotechnology leader in gene therapy for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease–complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy–late stage age-related macular degeneration.